antalarmin has been researched along with acamprosate in 1 studies
| Studies (antalarmin) | Trials (antalarmin) | Recent Studies (post-2010) (antalarmin) | Studies (acamprosate) | Trials (acamprosate) | Recent Studies (post-2010) (acamprosate) |
|---|---|---|---|---|---|
| 181 | 0 | 76 | 659 | 137 | 235 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cador, M; Koob, GF; Stinus, L; Zorrilla, EP | 1 |
1 other study(ies) available for antalarmin and acamprosate
| Article | Year |
|---|---|
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Topics: Acamprosate; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Avoidance Learning; Buprenorphine; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Implants; Fluoxetine; Lisuride; Male; Morphine; Naloxone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Substance Withdrawal Syndrome; Taurine | 2005 |